Updates from EHA 2024: Review of PERSEUS and IsKIA
Multiple myeloma specialists analyze recent findings presented at EHA 2024, offering expert perspectives on the PERSEUS and IsKIA clinical trials and their implications for patient care.
EP: 1.Transplant Eligible Multiple Myeloma: Current Standard of Care and Treatment Landscape
EP: 2.Updates from EHA 2024: Review of PERSEUS and IsKIA
EP: 3.Clinical Implications of Updated Data from EHA 2024
EP: 4.Updated Data from EHA 2024: Transplant Ineligible NDMM
EP: 5.Impact of CAR T-cell therapy in Earlier Lines of MM
EP: 6.CAR T-cell therapy in MM: Updated Data and the Future
Video content above is prompted by the following:
- Please briefly review updates and discuss the clinical implications from the trials.
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
